Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome

Corcept Therapeutics Incorporated CORT today announced that it has submitted its New Drug Application for the use of CORLUX in Cushing's Syndrome to the U.S. Food and Drug Administration.